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Abstract
Background: Lack of transparency in clinical trial conduct, publication bias and selective reporting bias are still important
problems in medical research. Through clinical trials registration, it should be possible to take steps towards resolving some
of these problems. However, previous evaluations of registered records of clinical trials have shown that registered
information is often incomplete and non-meaningful. If these studies are accurate, this negates the possible benefits of
registration of clinical trials.
Methods and Findings: A 5% sample of records of clinical trials that were registered between 17 June 2008 and 17 June
2009 was taken from the International Clinical Trials Registry Platform (ICTRP) database and assessed for the presence of
contact information, the presence of intervention specifics in drug trials and the quality of primary and secondary outcome
reporting. 731 records were included. More than half of the records were registered after recruitment of the first participant.
The name of a contact person was available in 94.4% of records from non-industry funded trials and 53.7% of records from
industry funded trials. Either an email address or a phone number was present in 76.5% of non-industry funded trial records
and in 56.5% of industry funded trial records. Although a drug name or company serial number was almost always provided,
other drug intervention specifics were often omitted from registration. Of 3643 reported outcomes, 34.9% were specific
measures with a meaningful time frame.
Conclusions: Clinical trials registration has the potential to contribute substantially to improving clinical trial transparency
and reducing publication bias and selective reporting. These potential benefits are currently undermined by deficiencies in
the provision of information in key areas of registered records.
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Introduction
Many instances of unethical research conduct by clinical trial
sponsors and investigators have come to light over the past decade.
The types of misconduct vary and include not obtaining approval
from research ethics committees, not obtaining informed consent
from trial participants and the fabrication of data [1–5]. Despite the
ethical obligation to accurately report the results of research in
humans [6], some trial sponsors have deliberately withheld negative
outcome information when publishing the findings of clinical trials,
and when making the trial findings available to regulatory
authorities [7–9]. Such behaviour is particularly concerning when
the misconduct involves trials recruiting participants in low and
middle income countries with deficient oversight mechanisms [5].
Prospectively registering clinical trials can potentially prevent at
least some of this misconduct from occurring, specifically selective
reporting, by putting key protocol information about each trial in the
public domain, ideally before the first participant is recruited to the
study. Five years have now passed since the International Committee
of Medical Journal Editors (ICMJE) first published its statement
requiring registration as a precondition of publication [10], and the
World Health Assembly approved the establishment of the
International Clinical Trials Registry Platform (ICTRP) by the
World Health Organization (WHO). Today the ICTRP provides
free access via a single web portal to more than 120,000 records of
registered trials made available by clinical trial registries around the
world [11]. In the intervening years the number of countries and
agencies that have created and implemented their own policies on
trial registration has increased, including the World Medical
Association which now explicitly states in the Declaration of Helsinki
that prospective registration is an ethical requirement [6,12–24].
Prospective registration can only contribute to the more ethical
conduct of clinical trials however, if all of the key information about
the trial is registered, and the registered data are meaningful. The
ICMJE agrees that quality is important and states that missing or
uninformative entries in any of the fields required by the WHO 20-
item Trial Registration Data Set is inadequate [25,26]. The quality
of registered data has been called into question of late, with
particular concerns regarding the quality of contact information
[27–31], intervention details, [27,30–33] and the outcomes (and
outcome measures) being used [27,31,33–36]. Poor data quality
raises doubt on the ability of trial registration to meet the challenge
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adequately address publication bias and selective reporting, and
reducing the amount of wasted research [37–39].
The objective of this study was therefore to determine whether
registered records of clinical trials contained complete and
meaningful data for key items in the WHO Trial Registration
Data Set [25]. Given the particular concern regarding the quality
of contact information, intervention details, and outcome
information, it was agreed that these data items would be the
focus of the study.
Methods
A random 5% sample of all clinical trial records of trials
registered as interventional between 17 June 2008 and 17 June
2009 was taken from the ICTRP database. Records of trials that
were registered as observational, records that pertained to US
Food and Drug Administration (FDA) lockbox device trials [40]
and records that were duplicate records (due to registration of a
trial in more than one register) were not eligible for the sample
[41]. For trials with multiple records the record with the earliest
registration date was considered eligible. At the time the sample
was taken the database included trials registered in nine different
registries.
About the data
The ICTRP Search Portal imports the WHO Trial Registration
Data Set from registries that meet WHO criteria, including
ClinicalTrials.gov. As the format of each data item differs across
registries, data is currently imported into the portal as text. The
ICTRP publishes a hyperlink to the record in the source registry
(i.e. the registry that provided the data) so users can view
additional information, if required.
Data extraction
Registry name, trial ID, target sample size, recruitment status,
date of registration, date of first enrolment and the public and
scientific title for each record were downloaded from the ICTRP
database and imported into Excel on 17 June 2009.
During manual searching of records, it became clear that
several records of trials that were registered as interventional were
in fact records of observational trials, diagnostic accuracy trials or
treatment protocols for continuation of treatment after inclusion in
a study protocol. These records were excluded from further data
extraction.
Descriptive information on study phase, study design, random-
ization status and inclusion criteria for gender and age of
participants was extracted manually from the complete registered
record in the source registry. Data on interventions and sponsorship
was also extracted manually and was then coded. The system used
to code interventions was adapted from the codes used for
intervention types on ClinicalTrials.gov [42]. Primary sponsors
were coded as being foundation, government, industry, university/
hospital, or other. Trials were coded as being industry funded
(primary sponsor was industry), partially industry funded (primary
sponsor was non-industry, but secondary sponsor or source of
monetary or material support was industry) or non-industry funded.
Contact information. The presence or absence of the
following contact details was evaluated: name of a contact
person (investigator or other), email address and telephone
number. The WHO 20-item Trial Registration Data Set
requires registration of separate scientific and public contact
details [25]. There was however variation in registration formats
for contact details between different registries. Some registries had
one field for contact details, others had two separate fields for
public and scientific contact details and others multiple contact
fields. For records with only one contact field the presence of
contact information was extracted from that field. For records with
multiple contact fields, if the contact details were present in any of
the fields, the information was denoted to be present.
Interventions. Given the considerable variability in the types
of interventions evaluated in trials, comparison of registration
quality between different intervention categories is difficult. It was
therefore decided to limit the evaluation of the quality of registered
intervention data to trials that investigated drugs, biologicals or
vaccines, including active comparators. Placebo comparators were
not evaluated. For each intervention and active comparator the
presence or absence of the following five intervention specifics was
collected: name, dose, duration of the intervention, frequency of
administration and route of administration. All intervention arms
were assessed separately. Name was denoted to be present if a
company serial number or a drug name was provided. Only
interventions and active comparators mentioned in the
intervention field were assessed. Other texts in the record were
scanned for additional information on mentioned interventions.
Outcome measures. The number of primary and secondary
outcomes per record was collected. Each primary and secondary
outcome was evaluated for specificity, using a classification system
adapted from the system used by Zarin et al in their assessment of
quality of outcomes [33]. If a record contained multiple outcomes,
all were assessed separately. Outcomes were classified as being a
specific measure, a domain, vague, an unexplained abbreviation,
or a part of safety monitoring.
Besides assessing the specificity of each outcome, the presence
or absence of a time frame was collected for every outcome. Some
outcomes assessed the duration of an event, the time to an event or
were safety monitoring outcomes. For these outcomes, reporting a
time frame is not possible, and the timeframe was therefore
denoted as irrelevant. Time frames were denoted to be not
meaningful when they did not specify a point in time when the
outcome was to be measured.
Only outcomes mentioned in the outcome fields were assessed.
Other texts in the record were scanned for additional information
on mentioned outcomes.
Pilot
Before starting data extraction a small pilot project was carried
out on 25 random records from the ICTRP database to test the
assessment framework. Results of the pilot were discussed by DG
and RV and the framework was subsequently adapted.
Assessment rules
All records were assessed for eligibility by RV who then
extracted and coded the data. During eligibility assessment and
data extraction trial records that were not covered by the
framework, or where that was ambiguous, were further assessed
by DG. Conflicts were resolved by mutual agreement.
A more detailed overview of the rules used in all assessments is
provided in supporting information file S1.
Analysis
Odds ratios and Pearson’s chi-squares were calculated to assess
the relationship between sources of funding and the presence of
contact details. For this purpose, partially industry funded trials
and non-industry funded trials were grouped together.
Completeness of registration of intervention specifics was
analysed according to funding source and trial phase. A binary
outcome variable was used that could be incomplete versus
Quality of Trial Registration
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entailed the reporting of drug name, dose, duration, frequency and
route. Funding source was categorized as in the analysis of contact
details. Trial phase was categorized to be Phase 0 or I versus other
(some trials were registered as being Phase I & II; these were
categorized as other). Regression analysis with robust estimation of
variance for clustered samples was used to assess whether these
variables influenced completeness of registration of intervention
specifics [43].
Quality of registration of primary outcomes was analysed
according to funding source, sample size category, trial phase and
intervention category. A binary outcome variable was used that
could be registration of a specific measure with a meaningful time
frame present or for which a time frame was irrelevant, versus any
other outcome. Funding source was categorized as in the analysis
of contact details. Trial phase was categorized as in the analysis of
intervention specifics. Sample size was categorized as being ,100
participants versus 100 or more participants. Interventions were
categorized to being either drug, biological or vaccine versus other
interventions. Regression analysis with robust estimation of
variance for clustered samples was used to assess whether these
variables influenced the quality of registration of primary
outcomes [43].
Statistical analyses were performed using SPSS version 15.0.1
and STATA version 11.1.
Results
There were 754 records in our 5% sample. One record was
withdrawn by the registry and could not be assessed. 22 records
were excluded from data extraction because the corresponding
trials were of an observational or diagnostic accuracy study design
or were a treatment protocol for continuation of treatment after
inclusion in a study protocol. A total of 731 records were included
for data extraction, of which 439 investigated drugs, biologicals or
vaccines (Figure 1).
All information that had to be extracted manually from the
registered records was collected between 17 June 2009 and 11
August 2009. Baseline data on registry name, primary sponsor
category, intervention type, study phase, study design, randomi-
zation status and inclusion criteria for gender of participants are
presented in Table 1.
Records were additionally checked for the presence of entries
in the fields for recruitment status, date of first enrolment and
the public and scientific title. The former three were present in
all records, the latter was reported in 700 records (95.8%).
Furthermore, information was collected on sample size and age
of participants. Sample size was reported in 721 records
(98.6%). The median target sample size for these records was
68 [IQR 30–200]. Age of participants was reported in 700
records (95.8%). 89 records (12.2%) mentioned inclusion of
participants ,18 years of age. Finally, registration dates and
dates of first enrolment were compared. The majority of records
in our sample did not provide a day for the date of first
enrolment but only a month and a year, which limited this
analysis to comparing the month in which trials were registered
to the month in which the first participant was recruited. The
registration date was in a later month than the date of first
enrolment in 53.4% of records (median: 10 months). This
difference was more than one month in 43.6% of records.
Registration date and date of first enrolment were in the same
month in 20.7% of records. The registration date was in an
earlier month than the date of first enrolment in 26.0% of
records (median: 2 months).
Quality of registration of contact information
Overall, 81.0% of records reported a name of a contact person
(n=592). 59.4% of records provided an email address (n=434)
and 64.2% of records a telephone number (n=469). 68.7% of
records provided either an email address or a telephone number
(Table 2).
Industry funded trials were less likely to mention a name in their
registered records than partially industry funded trials or non-
industry funded trials (OR=15.9, 95% CI: 9.9–25.5, p,0.001).
Industry funded trials were also less likely to mention an email
address in their registered records (OR=3.6, 95% CI: 2.6–4.9,
p,0.001) or to mention a telephone number (OR=3.1, 95% CI:
2.2–4.2, p,0.001). There were no differences in the presence of
contact details between partially industry funded trials and non-
industry funded trials (p=0.28, p=0.18 and p=0.13 respectively).
Quality of registration of interventions involving drugs,
biological or vaccines
There were 439 records of trials that investigated drugs,
biologicals or vaccines. Intervention specifics were recorded for
726 experimental or active comparator arms. A name was
reported in 713 arms (98.2%). For dose, duration of the
intervention, frequency of administration and route of adminis-
tration, information was present in 512 (70.5%), 508 (70.0%), 550
(75.8%) and 535 (73.7%) arms respectively. 321 arms (44.2%)
were complete in registering intervention specifics.
Multiple logistic regression analysis showed that funding source
was not a significant predictor of completeness of registration of
intervention specifics (p=0.39), but that study phase was
(p,0.001). Additional univariate analyses were performed, which
confirmed that funding source was not a significant predictor of
intervention registration quality (p=0.34) and that trials that were
Phase 0 or I were more likely to be complete in reporting
intervention specifics than other trials (OR=2.7, 95% CI: 1.5–4.9,
p,0.001).
Quality of registration of outcome measures
The 731 included trial records reported 1271 primary outcomes
and 2372 secondary outcomes. 66.2% of records reported one
primary outcome, 17.5% reported two, 6.0% reported three and
9.2% reported four or more. The maximum number of primary
outcomes reported in one record was 24. Eight records (1.1%)
reported no primary outcome at all, and 149 records reported no
secondary outcomes (20.4%).
The degree of specificity of reported outcomes was assessed
(Table 3). 38.2% of primary outcomes, 33.2% of secondary
outcomes and 34.9% of primary and secondary outcomes
combined were specific measures, for which a time frame was
irrelevant or for which a meaningful time frame was present.
Multiple logistic regression analysis showed that funding source
(p=0.30), target sample size (p=0.93), intervention category
(p=0.39) and study phase (p=0.70) were all not significant as
predictors for the reporting of specific measures with a meaningful
time frame present (or irrelevant). Additional univariate analyses
were performed, which confirmed that none of the dependent
variables were significant predictors of outcome registration
quality (p=0.24, p=0.33, p=0.49 and p=0.46 respectively).
Discussion
To be able to fulfil the promise of clinical trials registration, it is
of paramount importance that registration is comprehensive,
complete and accurate. That is, that all trials in all countries are
registered, that meaningful data are registered for every item in the
Quality of Trial Registration
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are correct and up-to-date. This study confirms the findings of
similar studies that have shown that the quality of registered trial
data is a significant problem and that it needs to be improved.
There should be clearly assigned responsibility to a named
Principal Investigator in all registered records of clinical trials to
facilitate investigator accountability and transparency [29]. By
Principal Investigator (PI) we mean ‘‘the individual who is
responsible and accountable for conducting the clinical trial’’
[25]. In 2008 Sekeres et al examined 1388 clinical trial register
entries and found that all 440 registered trial records with
recruitment status ‘‘in progress’’ that were either non- or partially
funded by industry named the scientific leadership of the trial,
compared with 49% (111/226) of those funded by industry;
findings confirmed by the current study.
There are well-established ethical, scientific and legal obliga-
tions associated with being a clinical trial investigator. Interna-
tional research standards such as the International Conference on
Harmonization (ICH) Topic E6 require investigators to have
appropriate qualifications and experience, to ensure compliance
with the trial protocol, to obtain and document informed consent,
and to be responsible for the medical care of trial subjects and for
Figure 1. Flowchart.
doi:10.1371/journal.pone.0014701.g001
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international standards (ICH E6, Declaration of Helsinki) do not
specifically require trials to have named scientific leadership, it
seems reasonable to ask for them to be publicly named and
accountable for the trials onto which they recruit participants,
considering their responsibilities both to the participants they
recruit, and to future patients who may benefit from the results of
the study [6]. Similarly, it is important that investigators be
contactable should the publication of the results of their research
be delayed (or not achieved, despite increasing public and legal
pressure to do so), to enable the results of studies to be made
available to investigators of similar studies and meta-analysts [45].
The PI is also ultimately responsible for registering the trial and
hence for the quality of the registered data. Some of the problems
Table 1. General descriptive information.
Category
Number of
records
Percentage of records
(%)
Registry name
1
ANZCTR 26 3.6
ChiCTR 11 1.5
ClinicalTrials.gov 628 85.9
CTRI 4 0.5
DRKS 2 0.3
IRCT 4 0.5
ISRCTN 39 5.3
NTR 16 2.2
SLCTR 1 0.1
Primary sponsor
Foundation 10 1.4
Government 39 5.3
Industry 246 33.7
University/hospital 398 54.4
Other
2 37 5.1
Not specified 1 0.1
Intervention type
3
Drug 385 52.7
Biological/vaccine 82 11.2
Device 49 6.7
Procedure/surgery 69 9.4
Radiation 23 3.1
Behavioural 76 10.4
Genetic
4 14 1.9
Dietary supplements 53 7.3
Physical therapy 23 3.1
Organizational 21 2.9
Diagnostic 9 1.2
Other 16 2.2
Study phase
5
0 10 1.4
I 106 14.5
I & II 38 5.2
II 122 16.7
II & III 16 2.2
III 101 13.8
IV 85 11.6
Not specified 253 34.6
Study design
Single arm 162 22.2
Controlled 458 62.7
Crossover 79 10.8
Not specified 32 4.4
Randomization
6
Randomized 518 70.9
Non-randomized 23 3.1
Not specified 29 4.0
Not applicable 161 22.0
Table 2. Presence of contact details by funding source.
Name Email
Telephone
nr.
Email or tel.
nr.
Industry (N=246) N 132 96 115 139
% 53.7 39.0 46.7 56.5
Partially industry
(N=76)
N 74 48 50 50
% 97.4 63.2 65.8 65.8
Non-industry
(N=408)
N 385 289 303 312
% 94.4 70.8 74.3 76.5
Overall (N=731)
1 N 592 434 469 502
% 81.0 59.4 64.2 68.7
1For one trial, no primary sponsor was registered.
doi:10.1371/journal.pone.0014701.t002
Category
Number of
records
Percentage of records
(%)
Gender
M 39 5.3
F 79 10.8
Both 599 81.9
Not specified 14 1.9
Total per category 731 100
1Registry acronyms stand for: Australian New Zealand Clinical Trials Registry
(ANZCTR), Chinese Clinical Trial Register (ChiCTR), Clinical Trials Registry - India
(CTRI), German Clinical Trials Register (DRKS), Iranian Registry of Clinical Trials
(IRCT), International Standard Randomized Controlled Trial Number Register
(ISRCTN), The Netherlands National Trial Register (NTR), Sri Lanka Clinical Trials
Registry (SLCTR).
2Other sponsors consisted of persons that were registered as primary sponsor,
non-governmental organizations, collaborative research institutions and
clinical research organizations.
3Overlap was possible, total in this category is greater than 731.
4Genetic interventions consisted of gene transfer therapy and somatic cell
transplants.
5The presence of study phase in records was analysed separately for trials in
drugs, biologicals or vaccines. Of 439 trials researching these types of
interventions, study phase was reported in 370 records (84.3%).
6For single arm trials, randomization is not applicable. However, one single arm
trial was registered as being randomized.
doi:10.1371/journal.pone.0014701.t001
Table 1. Cont.
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solved by having a named PI in the registry record.
Arguably the two most important pieces of information about a
clinical trial that need to be registered are the description of the
interventions being compared, and the outcomes upon which any
conclusion about the safety and effectiveness of the interventions
will be made. As demonstrated by this and previous studies, the
quality of this information, as it has been registered to date, has
been poor [27,30–36].
In 2005, nine to ten percent of registered trial records on
ClinicalTrials.gov provided an incomplete or nonspecific descrip-
tion of the intervention name [30,33]. Although subsequent studies
suggest that this has improved to less than two or three percent
[33,34,46], more information is required about the intervention
than the name. There should also be a description that is detailed
enough for it to be possible to distinguish between the arms of the
study. For trials of drugs, biologicals and vaccines this means
information on the dose, frequency, route of administration and
duration of treatment [25,47]. In the current study less than half of
the intervention arms where this information was relevant
provided it. That there is room for improvement is confirmed
by the fact that records of some trials (Phase 0 and I) describe
interventions in greater detail, perhaps due to a greater focus on
the specifics of the intervention in these trials.
Similarly, more is required when registering trial outcomes
than the name. To be complete the record should contain the
name of the outcome, information on the instrument that is being
used to measure it (when applicable), and the time points at
which it will be measured. Primary outcomes with a specific
measure and a meaningful time frame were registered in only
31% of records evaluated by Zarin et al in 2005, and in 38% of
records in the current study [33]. Given the critical importance of
the primary outcome to the scientific integrity of the study it is of
enormous concern that this key information is still not being
made public in a way that is meaningful or informative. Since the
primary outcome is the one that the study should be designed to
evaluate, and hence used to calculate the sample size, it is also
concerning that so many trials claim to have multiple primary
outcomes with almost one in ten trials claiming four or more. The
combined problem of multiple primary outcomes, lack of
specification of the instrument being used to measure the
outcome, and non-reporting of time frames leaves the door open
for fishing expeditions and will not solve the problem of selective
reporting bias.
The trial records in this study were registered between June
2008 and June 2009 on any one of the nine registries that provided
data to the ICTRP Search Portal, including ClinicalTrials.gov.
Although the latter is the most established and clearly the largest
registry, 14% of the records in this study were provided by the
other registries. As more countries seek to improve the
transparency of clinical trial research involving nationals of that
country, to be more accountable to the individuals who consent to
participate in clinical research, to better oversee and monitor that
research, and to make information accessible in the languages
spoken by the nationals of each country, it is inevitable that the
number of trial registries will increase [48]. Since the start of this
study, the number of registries that provide data to the ICTRP has
already risen from nine to twelve.
Prospective registration is defined by the ICMJE and WHO as
registration of a clinical trial before recruitment of the first
participant. Even allowing amnesty for trials registered in
compliance with national laws (such as the Food and Drug
Administration Amendments Act in the US), more than 40% of
the records in our sample were registered one month or more after
recruitment of the first participant, with a median time to
registration of 10 months for retrospectively registered trials. Data
from the Australian New Zealand Clinical Trials Registry
(ANZCTR) confirm these findings and show no improvement for
2010 (Personal communication, L. Askie, 29 June 2010). This delay
is clearly not acceptable, particularly as many trials could feasibly
complete recruitment in such a time frame and could potentially
then retrospectively register the trial in a way that could favour a
particular result. It is for this reason that some registries refuse to
retrospectively register trials. Adoption and enforcement of the ICMJE
policy on prospective registration by more journal editors could
make an important difference, and some key journals are playing a
leading role in this regard [49]. By emphasizing the importance of
informative entries and specifically underlining the consequences of
omitting information, journal editors could contribute even more to
the attainment of high quality registration.
Table 3. Degree of specificity of primary and secondary outcomes.
Primary outcomes
(N=1271)
Secondary outcomes
(N=2372)
Primary and secondary
outcomes (N=3643)
Classification Examples
Specific measure (%) 47.1 42.5 44.1 All-cause mortality, quality of life by SF-36,
pulmonary functioning by FEV-1
Domain (%) 36.7 38.7 38.0 Freedom from progression, quality of life,
pulmonary functioning
Vague (%) 5.4 6.5 6.1 Efficacy, symptoms, laboratory parameters
Unexplained abbreviation (%) 3.5 4.6 4.2 Any unexplained abbreviation
Safety monitoring (%) 7.3 7.8 7.6 Adverse event monitoring, drug toxicities,
complications
Time
Time present (%) 65.9 62.7 63.8 Mortality at one year
Time present, not meaningful (%) 10.8 13.7 12.7 ECG twice a year, social impact throughout study
Time absent (%) 7.7 9.2 8.7
Time irrelevant (%) 15.6 14.4 14.8 Duration of stay in ICU, time to progression
doi:10.1371/journal.pone.0014701.t003
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records is not the same as a study of the quality of the design or
conduct of clinical trials. It is just as possible that the trials that
have not been adequately registered are of high quality as low
quality. However, just as the quality of a trial and its results can
usually only be assessed against the quality of the publication
reporting those results, in the absence of the complete protocol we
have no other choice than to judge the quality of a trial’s design
against the information entered into a trial registry.
It has now been five years since the ICMJE and the World
Health Assembly put their crucial support behind the need to
prospectively register clinical trials. In the time that has passed the
number of registered trials has increased from less than 10,000 to
more than 120,000, but a significant proportion of the information
that has been registered remains deficient. In an attempt to
improve the quality of registered data the WHO ICTRP has
introduced a number of measures. One is to improve the
explanatory text for the Trial Registration Data Set to make the
requirements for registration clearer, particularly for contact,
intervention and outcome information [25]. Another is the
establishment of International Standards for Clinical Trial
Registries, the aim of which is to improve the quality of registered
data by establishing a clear minimum requirement for quality
control processes performed and data recording practices used by
individual clinical trial registries. It is our intention to repeat this
study following the introduction of the standards and continue to
monitor the quality of registered data. If successful, these measures
could improve the meaningfulness and usefulness of registered
data, and hence ensure its scientific, ethical and moral integrity.
Supporting Information
Supporting Information File S1 Assessment rules. These
contain a more detailed explanation of the methods used to assess
the quality of registered records on the ICTRP database.
Found at: doi:10.1371/journal.pone.0014701.s001 (0.07 MB
DOC)
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